Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces

Journal of Immunology

Volumn 177, Issue 9, 2006, Pages 6308-6316

  Ferreira, Viviana P ^a   Herbert, Andrew P ^b   Hocking, Henry G ^b   Barlow, Paul N ^b   Pangburn, Michael K ^a,c  

^a UNIVERSITY OF TEXAS AT TYLER   (United States)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL SURFACE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT SYSTEM; CONTROLLED STUDY; ENDOTHELIUM CELL; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HUMAN CELL; KIDNEY PARENCHYMA; NONHUMAN; PRIORITY JOURNAL; SHEEP ERYTHROCYTE; THROMBOCYTE;

EID: 33750336175     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.177.9.6308     Document Type: Article

References (70)

1. Bettinaglio, C. J., P. F. Zipfel, B. Amadei, E. Daina, S. Gamba, C. Skerka, N. Marziliano, G. Remuzzi, and M. Noris. 2001. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J. Am. Soc. Nephrol. 12: 297-307.
2. Buddles, M. R. H., R. L. Donne, A. Richards, J. A. Goodship, and T. H. Goodship. 2000. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 66: 1721-1722.
3. Dragon-Durey, M. A., V. Fremeaux-Bacchi, C. Loirat, J. Blouin, P. Niaudet, G. Deschenes, P. Coppo, F. W. Herman, and L. Weiss. 2004. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J. Am. Soc. Nephrol. 15: 787-795.
4. Manuelian, T., J. Hellwage, S. Meri, J. Caprioli, M. Noris, S. Heinen, M. Jozsi, H. P. Neumann, G. Remuzzi, and P. F. Zipfel. 2003. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111: 1181-1190.
5. Pichette, V., S. Querin, W. Schurch, G. Brun, G. Lehner-Netsch, and J. M. Delage. 1994. Familial hemolytic-uremic syndrome and homozygous factor H deficiency. Am. J. Kidney Dis. 24: 936-943.
6. Richards, A., M. R. H. Buddles, R. L. Donne, B. S. Kaplan, E. Kirk, M. C. Venning, C. L. Tielemans, J. A. Goodship, and T. H. Goodship. 2001. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am. J. Hum. Genet. 68: 485-490.
7. Rodriguez de Cordoba, S., J. Esparza-Gordillo, E. Goicoechea de Jorge, M. Lopez-Trascasa, and P. Sanchez-Corral. 2004. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 41: 355-367.
8. Warwicker, P., T. H. Goodship, R. L. Donne, Y. Pirson, A. Nicholls, R. M. Ward, P. Turnpenny, and J. A. Goodship. 1998. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int. 53: 836-844.
9. Ying, L., Y. Katz, M. Schlesinger, R. Carmi, H. Shalev, N. Haider, G. Beck, V. C. Sheffield, and D. Landau. 1999. Complement factor H gene mutation associated with autosomal recessive atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 65: 1538-1546.
10. Zipfel, P. F., J. Hellwage, M. A. Friese, G. Hegasy, T. S. Jokiranta, and S. Meri. 1999. Factor H and disease: a complement regulator affects vital body functions. Mol. Immunol. 36: 241-248.
11. Heinen, S., P. Sanchez-Corral, M. S. Jackson, L. Strain, J. A. Goodship, E. J. Kemp, C. Skerka, T. S. Jokiranta, K. Meyers, E. Wagner, et al. 2006. De novo gene conversion in the RCA gene cluster (1q32) causes mutations in complement factor H associated with atypical hemolytic uremic syndrome. Hum. Mutat. 27: 292-293.
12. Atkinson, J. P., M. K. Liszewski, A. Richards, D. Kavanagh, and E. A. Moulton. 2005. Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue. Ann. NY Acad. Sci. 1056: 144-152.
13. Esparza-Gordillo, J., J. E. Goicoechea de, A. Bull, B. L. Carreras, M. Lopez-Trascasa, P. Sanchez-Corral, and C. S. de Rodriguez. 2005. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum. Mol. Genet. 14: 703-712.
14. Perez-Caballero, D., C. Gonzalez-Rubio, M. E. Gallardo, M. Vera, M. Lopez-Trascasa, S. Rodriguez de Cordoba, and P. Sanchez-Corral. 2001. Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am. J. Hum. Genet. 68: 478-484.
15. Perkins, S. J., and T. H. Goodship. 2002. Molecular modelling of the C-terminal domains of factor H of human complement: a correlation between haemolytic uraemic syndrome and a predicted heparin binding site. J. Mol. Biol. 316: 217-224.
16. Herbert, A. P., D. Uhrin, M. Lyon, M. K. Pangburn, and P. N. Barlow. 2006. Disease-associated sequence variations congregate in a polyanion-recognition patch on human factor H revealed in 3D structure. J. Biol. Chem. 281: 16512-16520.
17. Jokiranta, T. S., V. P. Jaakola, M. J. Lehtinen, M. Parepalo, S. Meri, and A. Goldman. 2006. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J. 25: 1784-1794.
18. Jokiranta, T. S., Z. Z. Cheng, H. Seeberger, M. Jozsi, S. Heinen, M. Noris, G. Remuzzi, R. Ormsby, D. L. Gordon, S. Meri, et al. 2005. Binding of complement factor H to endothelial cells is mediated by the carboxy-terminal glycosaminoglycan binding site. Am. J. Pathol. 167: 1173-1181.
19. Pickering, M., H. Cook, J. Warren, A. Bygrave, J. Moss, M. J. Walport, and M. Botto. 2002. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat. Genet. 31: 424-428.
20. Junnikkala, S., T. S. Jokiranta, M. A. Friese, H. Jarva, P. F. Zipfel, and S. Meri. 2000. Exceptional resistance of human H2 glioblastoma cells to complement-mediated killing by expression and utilization of factor H and factor H-like protein 1. J. Immunol. 164: 6075-6081.
21. Junnikkala, S., J. Hakulinen, H. Jarva, T. Manuelian, L. Bjorge, R. Butzow, P. F. Zipfel, and S. Meri. 2002. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br. J. Cancer 87: 1119-1127.
22. Blackmore, T. K., J. Hellwage, T. A. Sadlon, N. Higgs, P. F. Zipfel, H. M. Ward, and D. L. Gordon. 1998. Identification of the second heparin-binding domain in human complement factor H. J. Immunol. 160: 3342-3348.
23. Jarvis, G. A., and N. A. Vedros. 1987. Sialic acid of group B Neisseria meningitidis regulates alternative complement pathway activation. Infect. Immun. 55: 174-180.
24. Quin, L. R., S. Carmicle, S. Dave, M. K. Pangburn, J. P. Evenhuis, and L. S. McDaniel. 2005. In vivo binding of complement regulator factor H by Streptococcus pneumoniae. J. Infect. Dis. 192: 1996-2003.
25. Ram, S., A. K. Sharma, S. D. Simpson, S. Gulati, D. P. McQuillen, M. K. Pangburn, and P. A. Rice. 1998. A novel sialic acid binding site on factor H mediates serum resistance of sialylated Neisseria gonorrhoeae. J. Exp. Med. 187: 743-752.
26. Smith, H., J. A. Cole, and N. J. Parsons. 1992. The sialylation of gonococcal lipopolysaccharide by host factors: a major impact on pathogenicity. FEMS Microb. Lett. 79: 287-292.
27. Wetzler, L. M., K. Barry, M. S. Blake, and E. C. Gotschlich. 1992. Gonococcal lipopolysaccharide sialylation prevents complement-dependent killing by immune sera. Infect. Immun. 60: 39-43.
28. Hogasen, K., J. H. Jansen, T. E. Mollnes, J. Hovdenes, and M. Harboe. 1995. Hereditary porcine membranoproliferative glomerulonephritis type II is caused by factor H deficiency. J. Clin. Invest. 95: 1054-1061.
29. Kristensen, T., and B. F. Tack. 1986. Murine protein H is comprised of 20 repeating units, 61 amino acids in length. Proc. Natl. Acad. Sci. USA 83: 3963-3967.
30. Ripoche, J., A. J. Day, T. J. R. Harris, and R. B. Sim. 1988. The complete amino acid sequence of human complement factor H. Biochem. J. 249: 593-602.
31. Discipio, R. G. 1992. Ultrastructures and interactions of complement factors H and I. J. Immunol. 149: 2592-2599.
32. Moore, M. D., R. G. Discipio, N. R. Cooper, and G. R. Nemerow. 1989. Hydrodynamic, electron microscopic, and ligand-binding analysis of the Epstein-Barr virus/C3dg receptor (CR2). J. Biol. Chem. 264: 20576-20582.
33. Alsenz, J., J. D. Lambris, T. F. Schulz, and M. P. Dierich. 1984. Localization of the complement component C3b binding site and the cofactor activity for factor I in the 38 kDa tryptic fragment of factor H. Biochem. J. 224: 389-398.
34. Blackmore, T. K., T. A. Sadlon, H. M. Ward, D. M. Lublin, and D. L. Gordon. 1996. Identification of a heparin binding domain in the seventh short consensus repeat of complement factor H. J. Immunol. 157: 5422-5427.
35. Gordon, D. L., R. M. Kaufman, T. K. Blackmore, J. Kwong, and D. M. Lublin. 1995. Identification of complement regulatory domains in human factor H. J. Immunol. 155: 348-356.
36. Kühn, S., C. Skerka, and P. F. Zipfel. 1995. Mapping of the complement regulatory domains in the human factor H-like protein 1 and in factor H. J. Immunol. 155: 5663-5670.
37. Meri, S., and M. K. Pangburn. 1990. Discrimination between activators and non-activators of the alternative pathway of complement: regulation via a sialic acid/polyanion binding site on factor H. Proc. Natl. Acad. Sci. USA 87: 3982-3986.
38. Ormsby, R. J., T. S. Jokiranta, T. G. Duthy, K. M. Griggs, T. A. Sadlon, E. Giannakis, and D. L. Gordon. 2006. Localization of the third heparin-binding site in the human complement regulator factor H. Mol. Immunol. 43: 1624-1632.
39. Pangburn, M. K., M. A. L. Atkinson, and S. Meri. 1991. Localization of the heparin-binding site on complement factor H. J. Biol. Chem. 266: 16847-16853.
40. Sharma, A. K., and M. K., Pangburn. 1996. Identification of three physically and functionally distinct binding sites for C3b in human complement factor H by deletion mutagenesis. Proc. Natl. Acad. Sci. USA 93: 10996-11001.
41. Jokiranta, T. S., P. F. Zipfel, J. Hakulinen, S. Kuhn, M. K. Pangburn, J. D. Tamerius, and S. Meri. 1996. Analysis of the recognition mechanism of the alternative pathway of complement by monoclonal anti-factor H antibodies: evidence for multiple interactions between H and surface bound C3b. FEBS Lett. 393: 297-302.
42. Jokiranta, T. S., J. Hellwage, V. Koistinen, P. F. Zipfel, and S. Meri. 2000. Each of the three binding sites on factor H interacts with a distinct site on C3b. J. Biol. Chem. 275: 27657-27662.
43. Pangburn, M. K., M. Shreedhar, N. Alam, N. Rawal, A. Herbert, and A. Haque. 2004. Functional analysis of each of the three C3b binding sites of factor H and comparison with full length factor H. Mol. Immunol. 41: 291.
44. Kuhn, S., and P. F. Zipfel. 1996. Mapping of the domains required for decay acceleration activity of the human factor H-like protein 1 and factor H. Eur. J. Immunol. 26: 2383-2387.
45. Pangburn, M. K., R. D. Schreiber, and H. J. Muller-Eberhard. 1977. Human complement C3b inactivator, isolation, characterization, and demonstration of an absolute requirement for the serum protein BIH for cleavage of C3b and C4b in solution. J. Exp. Med. 146: 257-270.
46. Prodinger, W. M., J. Hellwage, M. Spruth, M. P. Dierich, and P. F. Zipfel. 1998. The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem. J. 331(Pt. 1): 41-47.
47. Fearon, D. T. 1978. Regulation by membrane sialic acid of BIH-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc. Natl. Acad. Sci. USA 75: 1971-1975.
48. Pangburn, M. K., and H. J. Muller-Eberhard. 1978. Complement C3 convertase: cell surface restriction of BIH control and generation of restriction on neuraminidase treated cells. Proc. Natl. Acad. Sci. USA 75: 2416-2420.
49. Edwards, A. O., R. I. Ritter, K. J. Abel, A. Manning, C. Panhuysen, and L. A. Farrer. 2005. Complement factor H polymorphism and age-related macular degeneration. Science 308: 421-424.
50. Haines, J. L., M. A. Hauser, S. Schmidt, W. K. Scott, L. M. Olson, P. Gallins, K. L. Spencer, S. Y. Kwan, M. Noureddine, J. R. Gilbert, et al. 2005. Complement factor H variant increases the risk of age-related macular degeneration. Science 308: 419-421.
51. Klein, R. J., C. Zeiss, E. Y. Chew, J.-Y. Tsai, R. S. Sackler, C. Haynes, A. K. Henning, J. P. SanGiovanni, S. M. Mane, S. T. Mayne, et al. 2005. Complement factor H polymorphism in age-related macular degeneration. Science 308: 385-389.
52. Hageman, G. S., D. H. Anderson, L. V. Johnson, L. S. Hancox, A. J. Taiber, L. I. Hardisty, J. L. Hageman, H. A. Stockman, J. D. Borchardt, K. M. Gehrs, et al. 2005. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc. Natl. Acad. Sci. USA 102: 7227-7232.
53. Hammer, C. H., G. H. Wirtz, L. Renfer, H. D. Gresham, and B. F. Tack. 1981. Large scale isolation of functionally active components of the human complement system. J. Biol. Chem. 256: 3995-4006.
54. Pangburn, M. K. 1987. A fluorimetric assay for native C3: the hemolytically active form of the third component of human complement. J. Immunol. Methods 102: 7-14.
55. Gotze, O., and H. J. Muller-Eberhard. 1971. The C3-activator system: an alternative pathway of complement activation. J. Exp. Med. 134: 90s-108s.
56. Lesavre, P. H., T. E. Hugli, A. F. Esser, and H. J. Muller-Eberhard. 1979. The alternative pathway C3/C5 convertase: chemical basis of factor B activation. J. Immunol. 123: 529-534.
57. Christopherson, R. I. 1983. Desalting protein solutions in a centrifuge column. Methods Enzymol. 91: 278-281.
58. Rawal, N., and M. K. Pangburn. 1998. CS convertase of the alternative pathway of complement. Kinetic analysis of the free and surface-bound forms of the enzyme. J. Biol. Chem. 273: 16828-16835.
59. Fishelson, Z., and H. J. Muller-Eberhard. 1982. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium. J. Immunol. 129: 2603-2607.
60. Pangburn, M. K., R. D. Schreiber, and H. J. Muller-Eberhard. 1983. Deficiency of an erythrocyte membrane protein with complement regulatory activity in paroxysmal nocturnal hemoglobinuria. Proc. Natl. Acad. Sci. USA 80: 5430-5434.
61. Fearon, D. T., and K. F. Austen. 1977. Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J. Exp. Med. 146: 22-33.
62. Pangburn, M. K., K. L. W. Pangburn, V. Koistinen, S. Meri, and A. K. Sharma. 2000. Molecular mechanisms of target recognition in an innate immune system: interactions among factor H, C3b and target in the alternative pathway of human complement. J. Immunol. 164: 4742-4751.
63. Devine, D. V. 1991. The regulation of complement on cell surfaces. Transfus. Med. Rev. 5: 123-131.
64. Morgan, B. P., and C. L. Harris. 1998. Regulation in the activation pathways. In Complement Regulatory Proteins, 2nd Ed. Academic Press, San Diego, pp. 32-170.
65. Corey, M. J., R. J. Kinders, C. M. Poduje, C. L. Bruce, H. Rowley, L. G. Brown, G. M. Hass, and R. L. Vessella. 2000. Mechanistic studies of the effects of anti-factor H antibodies on complement-mediated lysis. J. Biol. Chem. 275: 12917-12925.
66. Cheng, Z. Z., M. J. Corey, M. Parepalo, S. Majno, J. Hellwage, P. F. Zipfel, R. J. Kinders, M. Raitanen, S. Meri, and T. S. Jokiranta. 2005. Complement factor H as a marker for detection of bladder cancer. Clin. Chem. 51: 856-863.
67. Nilsson, B., K.-E. Svensson, P. Borwell, and U. R. Nilsson. 1987. Production of mouse monoclonal antibodies that detect distinct neoantigenic epitopes on bound C3b and iC3b but not on the corresponding soluble fragments. Mol. Immunol. 24: 487-494.
68. Oppermann, M., T. Manuelian, M. Jozsi, E. Brandt, T. S. Jokiranta, S. Heinen, S. Meri, C. Skerka, O. Gotze, and P. F. Zipfel. 2006. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin. Exp. Immunol. 144: 342-352.
69. Ruggenenti, P., M. Noris, and G. Remuzzi. 2001. Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney Int. 60: 831-846.
70. Lang, P. A., O. Beringer, J. P. Nicolay, O. Amon, D. S. Kempe, T. Hermle, P. Attanasio, A. Akel, R. Schafer, B. Friedrich, et al. 2006. Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J. Mol. Med. 84: 378-388.